Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077312 | 0.82 | ADRA1D (0.43) | ADRA1DSMN1; SMN2ADRA1AADRA1BADRA2A | |
| SCHEMBL14401738 | 0.81 | ADRA1D (0.44) | ADRA1DSMN1; SMN2ADRA1AADRA1BADRA2A | |
| SCHEMBL6077299 | 0.78 | ADRA1D (0.43) | ADRA1DSMN1; SMN2ADRA1AADRA1BADRA2A | |
| SCHEMBL13180014 | 0.78 | KDM4E (0.42) | ADRA1DSMN1; SMN2ADRA1AADRA1BADRA2A | |
| SCHEMBL6077476 | 0.76 | IDO1 (0.48) | SMN1; SMN2KDM4ENTRK1 | |
| SCHEMBL5124506 | 0.75 | MAOA (0.39) | ADRA1DADRA1AADRA1BADRA2AADRA2C | |
| SCHEMBL4012771 | 0.75 | ADRA1D (0.39) | ADRA1DSMN1; SMN2ADRA1AADRA1BADRA2A | |
| SCHEMBL31488381 | 0.75 | P2RX7 (0.41) | SMN1; SMN2KDM4EHTTSLC6A4 | |
| SCHEMBL1151151 | 0.75 | CA12 (0.43) | ADRA1DSMN1; SMN2ADRA1AADRA1BUSP2 | |
| SCHEMBL6076860 | 0.73 | SLC6A2 (0.44) | HTTSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | ADRA1D 2563/4885SMN1; SMN2 4612/4885ADRA1A 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.